Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
NCT06087653
Recruiting
Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * • To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. * • Evaluate changes in efficacy indicators including objective response rate (ORR), progression-free survival (PFS), and duration... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Gabrail Cancer & Research Center, Canton, Ohio
Conditions: Multiple Myeloma
Register for Updates
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NCT05701358
Recruiting
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Acute Myocardial Infarction, Coronary Artery Disease
Register for Updates
Randomized Trial on Mobile Technology and Young Drivers' Cellphone Use
NCT05163119
Recruiting
The purpose of this study is to conduct a randomized controlled trial to determine the effects of a cellphone app and a driving mode intervention on driving behavior in drivers aged 18-24 years.
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
06/16/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Cell Phone Use, Automobile Driving
Register for Updates
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Cleveland Clinic Main Campus, Cleveland, Ohio
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
NCT04421248
Recruiting
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high levels of impulsivity and hyperactivity. They are at substantially increased risk for long-term difficulties into adulthood, including academic underachievement, substance abuse, and criminal behavior. The diagnosis of ADHD, which is based on subjective ratings by parents and teachers, likely results fr... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/16/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Attention Deficit Hyperactivity Disorder Combined
Register for Updates
Evolutionary Therapy for Rhabdomyosarcoma
NCT04388839
Recruiting
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Rhabdomyosarcoma
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT04569747
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Register for Updates
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: Stefanie Spielman Comprehensive Breast Center at Olentangy River Road, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481
Recruiting
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with ntvPPA.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
06/13/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Register for Updates
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
NCT06998056
Recruiting
This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
Gender:
ALL
Ages:
Between 3 months and 2 years
Trial Updated:
06/13/2025
Locations: Arcutis Clinical Study Site 220, Mason, Ohio
Conditions: Atopic Dermatitis (Eczema)
Register for Updates
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
06/13/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Post-ligation Cardiac Syndrome
Register for Updates